Photo for representation
Bhubaneswar: National Technical Advisory Group on Immunization (NTAGI) has approved Serum Institute of India’s COVID-19 vaccine Covovax for the 12-17 age group, sources told news agency ANI on Friday.
Notably, an expert panel of the country’s central drug authority recommended granting emergency use authorisation (EUA) to Covovax for this age group subject to certain conditions, on March 9. Subsequently, the Pune-based firm started to pursue regulatory permissions and its protocol.
Covovax has been developed through a technology transfer protocol from Novavax, which already has approval from the European medicines agency for conditional marketing authorisation.
India began inoculating children aged 12-14 on March 16 with Biological E’s Corbevax.
Mumbai: Former Bollywood actress Mamta Kulkarni, who was Shah Rukh Khan and Salman Khan’s co-star… Read More
Bhubaneswar: The Odisha government is all set to include over 3.5 crore people as beneficiaries… Read More
Srinagar: You may have heard of medical negligence before, but what happened in Kashmir recently is… Read More
Bhubaneswar: Odisha Chief Minister Mohan Charan Majhi on Friday distributed appointment letters to 6,390 new… Read More
Mumbai: Much talked-about star kids Junaid Khan and Khushi Kapoor's ‘Loveyapa’ was released in theatres… Read More
Bhubaneswar: Phonocon 2025, the 20th National Phono Surgery Conference, was inaugurated at KIMS here on… Read More
This website uses cookies.
